Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats

Yongho Lee, Mi Kyong Kwon, Eun Seok Kang, Young Mi Park, Seung Ho Choi, Chul Woo Ahn, Kyung Sub Kim, Chul Won Park, Bong Soo Cha, Sung Wan Kim, Je Kyung Sung, Eun Jig Lee, Hyun Chul Lee

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that plays an important role in glucose homeostasis. Its functions include glucose-stimulated insulin secretion, suppression of glucagon secretion, deceleration of gastric emptying, and reduction in appetite and food intake. Despite the numerous antidiabetic properties of GLP-1, its therapeutic potential is limited by its short biological half-life due to rapid enzymatic degradation by dipeptidyl peptidase IV. The present study aimed to demonstrate the therapeutic effects of constitutively expressed GLP-1 in an overt type 2 diabetic animal model using an adenoviral vector system. Methods: A novel plasmid (pAAV-ILGLP-1) and recombinant adenoviral vector (Ad-ILGLP-1) were constructed with the cytomegalovirus promoter and insulin leader sequence followed by GLP-1(7-37) cDNA. Results: The results of an enzyme-linked immunosorbent assay showed significantly elevated levels of GLP-1(7-37) secreted by human embryonic kidney cells transfected with the construct containing the leader sequence. A single intravenous administration of Ad-ILGLP-1 into 12-week-old Zucker diabetic fatty (ZDF) rats, which have overt type 2 diabetes mellitus (T2DM), achieved near normoglycemia for 3 weeks and improved utilization of blood glucose in glucose tolerance tests. Circulating plasma levels of GLP-1 increased in GLP-1-treated ZDF rats, but diminished 21 days after treatment. When compared with controls, Ad-ILGLP-1-treated ZDF rats had a lower homeostasis model assessment for insulin resistance score indicating amelioration in insulin resistance. Immunohistochemical staining showed that cells expressing GLP-1 were found in the livers of GLP-1-treated ZDF rats. Conclusions: These data suggest that GLP-1 gene therapy can improve glucose homeostasis in fully developed diabetic animal models and may be a promising treatment modality for T2DM in humans.

Original languageEnglish
Pages (from-to)260-268
Number of pages9
JournalJournal of Gene Medicine
Volume10
Issue number3
DOIs
Publication statusPublished - 2008 Mar 1

Fingerprint

Glucagon-Like Peptide 1
Genetic Therapy
Homeostasis
Glucose
Type 2 Diabetes Mellitus
Insulin Resistance
Animal Models
Insulin
Dipeptidyl Peptidase 4
Incretins
Deceleration
Gastric Emptying
Therapeutic Uses
Appetite
Glucose Tolerance Test
Glucagon
Cytomegalovirus
Hypoglycemic Agents
Intravenous Administration
Half-Life

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Drug Discovery
  • Genetics(clinical)

Cite this

Lee, Yongho ; Kwon, Mi Kyong ; Kang, Eun Seok ; Park, Young Mi ; Choi, Seung Ho ; Ahn, Chul Woo ; Kim, Kyung Sub ; Park, Chul Won ; Cha, Bong Soo ; Kim, Sung Wan ; Sung, Je Kyung ; Lee, Eun Jig ; Lee, Hyun Chul. / Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats. In: Journal of Gene Medicine. 2008 ; Vol. 10, No. 3. pp. 260-268.
@article{f6b89176880f421ca3f3aa28c0cdf344,
title = "Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats",
abstract = "Background: Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that plays an important role in glucose homeostasis. Its functions include glucose-stimulated insulin secretion, suppression of glucagon secretion, deceleration of gastric emptying, and reduction in appetite and food intake. Despite the numerous antidiabetic properties of GLP-1, its therapeutic potential is limited by its short biological half-life due to rapid enzymatic degradation by dipeptidyl peptidase IV. The present study aimed to demonstrate the therapeutic effects of constitutively expressed GLP-1 in an overt type 2 diabetic animal model using an adenoviral vector system. Methods: A novel plasmid (pAAV-ILGLP-1) and recombinant adenoviral vector (Ad-ILGLP-1) were constructed with the cytomegalovirus promoter and insulin leader sequence followed by GLP-1(7-37) cDNA. Results: The results of an enzyme-linked immunosorbent assay showed significantly elevated levels of GLP-1(7-37) secreted by human embryonic kidney cells transfected with the construct containing the leader sequence. A single intravenous administration of Ad-ILGLP-1 into 12-week-old Zucker diabetic fatty (ZDF) rats, which have overt type 2 diabetes mellitus (T2DM), achieved near normoglycemia for 3 weeks and improved utilization of blood glucose in glucose tolerance tests. Circulating plasma levels of GLP-1 increased in GLP-1-treated ZDF rats, but diminished 21 days after treatment. When compared with controls, Ad-ILGLP-1-treated ZDF rats had a lower homeostasis model assessment for insulin resistance score indicating amelioration in insulin resistance. Immunohistochemical staining showed that cells expressing GLP-1 were found in the livers of GLP-1-treated ZDF rats. Conclusions: These data suggest that GLP-1 gene therapy can improve glucose homeostasis in fully developed diabetic animal models and may be a promising treatment modality for T2DM in humans.",
author = "Yongho Lee and Kwon, {Mi Kyong} and Kang, {Eun Seok} and Park, {Young Mi} and Choi, {Seung Ho} and Ahn, {Chul Woo} and Kim, {Kyung Sub} and Park, {Chul Won} and Cha, {Bong Soo} and Kim, {Sung Wan} and Sung, {Je Kyung} and Lee, {Eun Jig} and Lee, {Hyun Chul}",
year = "2008",
month = "3",
day = "1",
doi = "10.1002/jgm.1153",
language = "English",
volume = "10",
pages = "260--268",
journal = "Journal of Gene Medicine",
issn = "1099-498X",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

Lee, Y, Kwon, MK, Kang, ES, Park, YM, Choi, SH, Ahn, CW, Kim, KS, Park, CW, Cha, BS, Kim, SW, Sung, JK, Lee, EJ & Lee, HC 2008, 'Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats', Journal of Gene Medicine, vol. 10, no. 3, pp. 260-268. https://doi.org/10.1002/jgm.1153

Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats. / Lee, Yongho; Kwon, Mi Kyong; Kang, Eun Seok; Park, Young Mi; Choi, Seung Ho; Ahn, Chul Woo; Kim, Kyung Sub; Park, Chul Won; Cha, Bong Soo; Kim, Sung Wan; Sung, Je Kyung; Lee, Eun Jig; Lee, Hyun Chul.

In: Journal of Gene Medicine, Vol. 10, No. 3, 01.03.2008, p. 260-268.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats

AU - Lee, Yongho

AU - Kwon, Mi Kyong

AU - Kang, Eun Seok

AU - Park, Young Mi

AU - Choi, Seung Ho

AU - Ahn, Chul Woo

AU - Kim, Kyung Sub

AU - Park, Chul Won

AU - Cha, Bong Soo

AU - Kim, Sung Wan

AU - Sung, Je Kyung

AU - Lee, Eun Jig

AU - Lee, Hyun Chul

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Background: Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that plays an important role in glucose homeostasis. Its functions include glucose-stimulated insulin secretion, suppression of glucagon secretion, deceleration of gastric emptying, and reduction in appetite and food intake. Despite the numerous antidiabetic properties of GLP-1, its therapeutic potential is limited by its short biological half-life due to rapid enzymatic degradation by dipeptidyl peptidase IV. The present study aimed to demonstrate the therapeutic effects of constitutively expressed GLP-1 in an overt type 2 diabetic animal model using an adenoviral vector system. Methods: A novel plasmid (pAAV-ILGLP-1) and recombinant adenoviral vector (Ad-ILGLP-1) were constructed with the cytomegalovirus promoter and insulin leader sequence followed by GLP-1(7-37) cDNA. Results: The results of an enzyme-linked immunosorbent assay showed significantly elevated levels of GLP-1(7-37) secreted by human embryonic kidney cells transfected with the construct containing the leader sequence. A single intravenous administration of Ad-ILGLP-1 into 12-week-old Zucker diabetic fatty (ZDF) rats, which have overt type 2 diabetes mellitus (T2DM), achieved near normoglycemia for 3 weeks and improved utilization of blood glucose in glucose tolerance tests. Circulating plasma levels of GLP-1 increased in GLP-1-treated ZDF rats, but diminished 21 days after treatment. When compared with controls, Ad-ILGLP-1-treated ZDF rats had a lower homeostasis model assessment for insulin resistance score indicating amelioration in insulin resistance. Immunohistochemical staining showed that cells expressing GLP-1 were found in the livers of GLP-1-treated ZDF rats. Conclusions: These data suggest that GLP-1 gene therapy can improve glucose homeostasis in fully developed diabetic animal models and may be a promising treatment modality for T2DM in humans.

AB - Background: Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that plays an important role in glucose homeostasis. Its functions include glucose-stimulated insulin secretion, suppression of glucagon secretion, deceleration of gastric emptying, and reduction in appetite and food intake. Despite the numerous antidiabetic properties of GLP-1, its therapeutic potential is limited by its short biological half-life due to rapid enzymatic degradation by dipeptidyl peptidase IV. The present study aimed to demonstrate the therapeutic effects of constitutively expressed GLP-1 in an overt type 2 diabetic animal model using an adenoviral vector system. Methods: A novel plasmid (pAAV-ILGLP-1) and recombinant adenoviral vector (Ad-ILGLP-1) were constructed with the cytomegalovirus promoter and insulin leader sequence followed by GLP-1(7-37) cDNA. Results: The results of an enzyme-linked immunosorbent assay showed significantly elevated levels of GLP-1(7-37) secreted by human embryonic kidney cells transfected with the construct containing the leader sequence. A single intravenous administration of Ad-ILGLP-1 into 12-week-old Zucker diabetic fatty (ZDF) rats, which have overt type 2 diabetes mellitus (T2DM), achieved near normoglycemia for 3 weeks and improved utilization of blood glucose in glucose tolerance tests. Circulating plasma levels of GLP-1 increased in GLP-1-treated ZDF rats, but diminished 21 days after treatment. When compared with controls, Ad-ILGLP-1-treated ZDF rats had a lower homeostasis model assessment for insulin resistance score indicating amelioration in insulin resistance. Immunohistochemical staining showed that cells expressing GLP-1 were found in the livers of GLP-1-treated ZDF rats. Conclusions: These data suggest that GLP-1 gene therapy can improve glucose homeostasis in fully developed diabetic animal models and may be a promising treatment modality for T2DM in humans.

UR - http://www.scopus.com/inward/record.url?scp=40549086289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40549086289&partnerID=8YFLogxK

U2 - 10.1002/jgm.1153

DO - 10.1002/jgm.1153

M3 - Article

C2 - 18085721

AN - SCOPUS:40549086289

VL - 10

SP - 260

EP - 268

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

SN - 1099-498X

IS - 3

ER -